Answers are grounded in this paper and cite their sources.
Pyroglutamate has been reported to be associated with many diseases such atherosclerosis, esophageal cancer, and COVID-19. However, it is still unclear about the role of blood pyroglutamate in Systemic Lupus Erythematosus (SLE). The present study used a two-sample Mendelian Randomization (MR) study to identify the potential causal association of pyroglutamine levels with SLE risk. Pyroglutamine-associated genetic Instrumental Variables (IVs) were chosen from the largest Genome-wide Association Studies (GWAS) for blood pyroglutamine-levels. The largest GWAS for SLE was employed to identify the potential causal association of blood pyroglutamine levels with SLE risk using a two-sample MR analysis. We successfully extracted three pyroglutamine-associated genetic IVs. Three IVs demonstrated no significant pleiotropy or heterogeneity in SLE GWAS. A two-sample MR analysis showed that as pyroglutamine genetically increased, the risk of SLE also increased using weighted median (OR = 3.994, 95% CI: [1.332 ∽ 11.970], p = 0.013) and Inverse Variance Weighted (IVW) (OR = 4.013, 95% CI: [1.484 ∽ 10.848], p = 0.006). Our analysis suggests a potential causal association of genetically increased pyroglutamine levels with increased SLE risk. Thus, pyroglutamine may be a potential risk factor for SLE.
No takes yet. Share an insight, caveat, or question.
Renxi Wang (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: